Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
REVEAL trial results and protocol alignment to enable a six-month interim analysis supporting a future Biologics License Application. This combination of regulatory recognition and clearer development path strengthens the company's position in Rett syndrome gene therapy and sharpens expectations around its lead program's potential path to market. Next, we'll examine how FDA Breakthrough Therapy Designation for TSHA-102 reshapes Taysha's investment narrative and future risk-reward profile. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Taysha Gene Therapies, you need to believe TSHA-102 can translate its Rett syndrome clinical signals and FDA Breakthrough Therapy Designation into an approvable, commercially meaningful product before cash pressure or competitors catch up. The latest protocol alignment and planned six month interim readout sharpen the timeline fo
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TSHA's page on the SEC website